http://orcid.org/0000-0003-4033-4614
Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Liu Li, Li Yang, Feng Yang, Xin-lan Zhao, Shengjiang Xue & Fang-hua Gong. (2021) Ginkgo biloba Extract 50 (GBE50) Ameliorates Insulin Resistance, Hepatic Steatosis and Liver Injury in High Fat Diet-Fed Mice. Journal of Inflammation Research 14, pages 1959-1971.
Read now
Read now
Wen Yuan, Meixing Yan, Yitong Wang, Xia Liu & Yanling Gong. (2021) Optimized preparation of eugenol microcapsules and its effect on hepatic steatosis in HepG2 cells. Drug Development and Industrial Pharmacy 47:2, pages 225-234.
Read now
Read now
Yong Rao, Zhiqi Kuang, Chan Li, Shiyao Guo, Yaohao Xu, Dandan Zhao, Yutao Hu, Bingbing Song, Zhi Jiang, Zhenhuang Ge, Xiyuan Liu, Chengdao Li, Shuobin Chen, Jiming Ye, Zhishu Huang & Yongjun Lu. (2021) Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes 13:1.
Read now
Read now
Yuanyuan Meng, Yong Liu, Ningning Fang & Yongmin Guo. (2019) Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat. Pharmaceutical Biology 57:1, pages 98-104.
Read now
Read now
Articles from other publishers (53)
Xia Niu, Yanan Meng, Jinjin Cui, Rui Li, Xiao Ding, Bingyu Niu, Ge Chang, Ning Xu, Guiling Li, Yucheng Wang & Lulu Wang. (2023) Hepatic Stellate Cell- and Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis. ACS Nano.
Crossref
Crossref
Yuanye Jiang, Xiaoyu Zhuang, Jiaqi Zhang, Meng Li, Shengnan Du, Jiyun Tian, Yifu Yuan, Guang Ji & Cheng Hu. (2023) Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease. Frontiers in Endocrinology 14.
Crossref
Crossref
Hossein Rafiei, Michelle Yeung, Sara Kowalski, Gerald Krystal & Ingrid Elisia. (2023) Development of a novel human triculture model of non-alcoholic fatty liver disease and identification of berberine as ameliorating steatosis, oxidative stress and fibrosis. Frontiers in Pharmacology 14.
Crossref
Crossref
Farnaz Sani, Mina Soufi Zomorrod, Negar Azarpira & Masoud Soleimani. (2023) The Effect of Mesenchymal Stem Cell-Derived Exosomes and miR17-5p Inhibitor on Multicellular Liver Fibrosis Microtissues. Stem Cells International 2023, pages 1-16.
Crossref
Crossref
Raghu Rai Sharma, Haroon Rashid & Sheikh Tasduq Abdullah. (2023) A small animal model of NASH with progressive steatohepatitis –induced by fast food diet and alcohol in C57BL/6J mouse with high human pathophysiological proximity. Food and Chemical Toxicology 178, pages 113851.
Crossref
Crossref
Adiya E. Otumala, Dominick J. Hellen, C. Alessandra Luna, Priscilla Delgado, Anjana Dissanayaka, Chidozie Ugwumadu, Oluwamayokun Oshinowo, Md. Mydul Islam, Luyao Shen, Saul J. Karpen & David R. Myers. (2023) Opportunities and considerations for studying liver disease with microphysiological systems on a chip. Lab on a Chip 23:13, pages 2877-2898.
Crossref
Crossref
Chao Yang, Jianguo Xu, Xiaomin Xu, Wen Xu, Bangzhuo Tong, Shulin Wang, Rujie Ji, Yan Tan & Ying Zhu. (2023) Characteristics of gut microbiota in patients with metabolic associated fatty liver disease. Scientific Reports 13:1.
Crossref
Crossref
Eric Simon, Maciej Motyka, Grietje H. Prins, Mei Li, Werner Rust, Stefan Kauschke, Coralie Viollet, Peter Olinga & Anouk Oldenburger. (2023) Transcriptomic profiling of induced steatosis in human and mouse precision-cut liver slices. Scientific Data 10:1.
Crossref
Crossref
Ying Shi, Xiaoguang Yang, Shuyue Wang, Yulun Wu, Lihua Zheng, Yufang Tang, Yanhang Gao & Junqi Niu. (2022) Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model. Stem Cell Research & Therapy 13:1.
Crossref
Crossref
Yichen Tong, Wentao Zhu, Tianzhi Wen, Zere Mukhamejanova, Fang Xu, Qi Xiang & Jiyan Pang. (2022) Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARα/PGC1α Signaling Pathway. Journal of Natural Products 85:7, pages 1738-1750.
Crossref
Crossref
Fuxiao Wei, Xinyue Yang, Meihong Zhang, Chang Xu, Yongfei Hu & Dan Liu. (2022) Akkermansia muciniphila Enhances Egg Quality and the Lipid Profile of Egg Yolk by Improving Lipid Metabolism. Frontiers in Microbiology 13.
Crossref
Crossref
Pengkai Wu, Xinping Luo, Meiling Sun, Beicheng Sun & Minjie Sun. (2022) Synergetic regulation of kupffer cells, extracellular matrix and hepatic stellate cells with versatile CXCR4-inhibiting nanocomplex for magnified therapy in liver fibrosis. Biomaterials 284, pages 121492.
Crossref
Crossref
Shanmugam Murugaiha Jeyakumar & Ayyalasomayajula Vajreswari. (2022) Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence. World Journal of Hepatology 14:1, pages 168-179.
Crossref
Crossref
Alex J. Wang, Allysa Allen, Marianna Sofman, Pierre Sphabmixay, Ece Yildiz & Linda G. Griffith. (2021) Engineering Modular 3D Liver Culture Microenvironments In Vitro to Parse the Interplay between Biophysical and Biochemical Microenvironment Cues on Hepatic Phenotypes. Advanced NanoBiomed Research 2:1, pages 2100049.
Crossref
Crossref
María Pelechá, Estela Villanueva-Bádenas, Enrique Timor-López, María Teresa Donato & Laia Tolosa. (2021) Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants 11:1, pages 86.
Crossref
Crossref
Jiongshan Zhang, Yue Li, Gemin Xiao, Yongwei Li, Heping Xie & Yan Chen. (2021) Fructooligosaccharides enhance the therapeutic effect of xiao-zhi-fang on non-alcoholic fatty liver disease via regulating intestinal flora. Liver Research 5:4, pages 217-223.
Crossref
Crossref
Tehila Daniel, Michaella Ben-Shachar, Elyashiv Drori, Sharleen Hamad, Anna Permyakova, Elad Ben-Cnaan, Joseph Tam, Zohar Kerem & Tovit Rosenzweig. (2021) Grape pomace reduces the severity of non-alcoholic hepatic steatosis and the development of steatohepatitis by improving insulin sensitivity and reducing ectopic fat deposition in mice. The Journal of Nutritional Biochemistry 98, pages 108867.
Crossref
Crossref
Kun Du, Shibo Li, Chengpan Li, Ping Li, Chunguang Miao, Tianzhi Luo, Bensheng Qiu & Weiping Ding. (2021) Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply. Acta Biomaterialia 134, pages 228-239.
Crossref
Crossref
Cui Guo, Yimin Xu, Xinyue Han, Xiaoqiang Liu, Runnan Xie, Zhihong Cheng & Xiaoling Fu. (2021) Transcriptomic and Proteomic Study on the High-Fat Diet Combined With AOM/DSS-Induced Adenomatous Polyps in Mice. Frontiers in Oncology 11.
Crossref
Crossref
Fatemeh Jafary Nia, Bahareh Yazdanparast Chaharmahali & Farah Nameni. (2021) Simultaneous Effect of Resistance Training and Alpha Lipoic Acid on Beclin-1 Expression and Malondialdehyde Level of Fatty Liver Diabetic Male Rats. Gene, Cell and Tissue 9:1.
Crossref
Crossref
Hiteshi Dhami-Shah, Rama Vaidya, Manasi Talwadekar, Eisha Shaw, Shobha Udipi, Ullas Kolthur-Seetharam & Ashok D.B. Vaidya. (2021) Intervention by picroside II on FFAs induced lipid accumulation and lipotoxicity in HepG2 cells. Journal of Ayurveda and Integrative Medicine 12:3, pages 465-473.
Crossref
Crossref
Nilay D. SolankiKirti VadiSandip Patel. (2021)
Alleviating effect of
Ficus racemosa
in high-fat-high-fructose diet-induced non-alcoholic fatty liver disease
. Indian Journal of Physiology and Pharmacology 65, pages 12-20.
Crossref
Crossref
Sushila Maharjan, Diana Bonilla, Princy Sindurakar, Hongbin Li, Wanlu Li, Sergio Duarte, Ali Zarrinpar & Y. Shrike Zhang. (2021) 3D human nonalcoholic hepatic steatosis and fibrosis models. Bio-Design and Manufacturing 4:2, pages 157-170.
Crossref
Crossref
Qiao-Ping Li, Yao-Xing Dou, Zi-Wei Huang, Han-Bin Chen, Yu-Cui Li, Jian-Nan Chen, Yu-Hong Liu, Xiao-Qi Huang, Hui-Fang Zeng, Xiao-Bo Yang, Zi-Ren Su & Jian-Hui Xie. (2021) Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. Phytomedicine 85, pages 153550.
Crossref
Crossref
Mario Rothbauer, Barbara E.M. Bachmann, Christoph Eilenberger, Sebastian R.A. Kratz, Sarah Spitz, Gregor Höll & Peter Ertl. (2021) A Decade of Organs-on-a-Chip Emulating Human Physiology at the Microscale: A Critical Status Report on Progress in Toxicology and Pharmacology. Micromachines 12:5, pages 470.
Crossref
Crossref
Mengyao Zhao, Shumin Chen, Xiaoguo Ji, Xin Shen, Jiangshan You, Xinyi Liang, Hao Yin & Liming Zhao. (2021) Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacological Research 166, pages 105517.
Crossref
Crossref
Emma L. Shepherd, Raquel Saborano, Ellie Northall, Kae Matsuda, Hitomi Ogino, Hiroaki Yashiro, Jason Pickens, Ryan E. Feaver, Banumathi K. Cole, Stephen A. Hoang, Mark J. Lawson, Matthew Olson, Robert A. Figler, John E. Reardon, Nobuhiro Nishigaki, Brian R. Wamhoff, Ulrich L. Günther, Gideon Hirschfield, Derek M. Erion & Patricia F. Lalor. (2021) Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. JHEP Reports 3:2, pages 100217.
Crossref
Crossref
Hyun‐Jong Cho, Han‐Jun Kim, KangJu Lee, Soufian Lasli, Aly Ung, Tyler Hoffman, Rohollah Nasiri, Praveen Bandaru, Samad Ahadian, Mehmet R. Dokmeci, Junmin Lee & Ali Khademhosseini. (2021) Bioengineered Multicellular Liver Microtissues for Modeling Advanced Hepatic Fibrosis Driven Through Non‐Alcoholic Fatty Liver Disease. Small 17:14, pages 2007425.
Crossref
Crossref
Sang Woo Lee, Da Jung Jung & Gi Seok Jeong. (2020) Gaining New Biological and Therapeutic Applications into the Liver with 3D In Vitro Liver Models. Tissue Engineering and Regenerative Medicine 17:6, pages 731-745.
Crossref
Crossref
Junyou Li, Mengqi Liu, Yazhou Li, Dan-dan Sun, Zhihao Shu, Qian Tan, Shimeng Guo, Rongrong Xie, Lixin Gao, Hongbo Ru, Yi Zang, Hong Liu, Jia Li & Yu Zhou. (2020) Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. Journal of Medicinal Chemistry 63:21, pages 12748-12772.
Crossref
Crossref
Dey Parama, Monikongkona Boruah, Kumari Yachna, Varsha Rana, Kishore Banik, Choudhary Harsha, Krishan Kumar Thakur, Uma Dutta, Aditya Arya, Xinliang Mao, Kwang Seok Ahn & Ajaikumar B. Kunnumakkara. (2020) Diosgenin, a steroidal saponin, and its analogs: Effective therapies against different chronic diseases. Life Sciences 260, pages 118182.
Crossref
Crossref
Roni F. Kunst, Marije Niemeijer, Luc J.W. van der Laan, Bart Spee & Stan F.J. van de Graaf. (2020) From fatty hepatocytes to impaired bile flow: Matching model systems for liver biology and disease. Biochemical Pharmacology 180, pages 114173.
Crossref
Crossref
Lu Guo, Jum Soon Kang, Young Hoon Park, Beong Il Je, Yong Jae Lee, Nam Jun Kang, Sun Young Park, Dae Youn Hwang & Young Whan Choi. (2020) S-petasin inhibits lipid accumulation in oleic acid-induced HepG2 cells through activation of the AMPK signaling pathway. Food & Function 11:6, pages 5664-5673.
Crossref
Crossref
Muhammed Majeed, Shaheen Majeed, Kalyanam Nagabhushanam, Lincy Lawrence & Lakshmi Mundkur. (2020) Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. Scientific Reports 10:1.
Crossref
Crossref
Tracey Hurrell, Vlasia Kastrinou-Lampou, Achilleas Fardellas, Delilah F. G. Hendriks, Åsa Nordling, Inger Johansson, Audrey Baze, Céline Parmentier, Lysiane Richert & Magnus Ingelman-Sundberg. (2020) Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis. Cells 9:4, pages 964.
Crossref
Crossref
Shabir Hassan, Shikha Sebastian, Sushila Maharjan, Ami Lesha, Anne‐Marie Carpenter, Xiuli Liu, Xin Xie, Carol Livermore, Yu Shrike Zhang & Ali Zarrinpar. (2020) Liver‐on‐a‐Chip Models of Fatty Liver Disease. Hepatology 71:2, pages 733-740.
Crossref
Crossref
Oh-Sung Kwon, Young-Kyu Kim, Kyu Hee Her, Hyeon Ju Kim & Seung Duk Lee. (2020) Physical activity can reduce the prevalence of gallstone disease among males. Medicine 99:26, pages e20763.
Crossref
Crossref
Katharina C. Reimer, Alexander Wree, Christoph Roderburg & Frank Tacke. (2019) New drugs for NAFLD: lessons from basic models to the clinic. Hepatology International 14:1, pages 8-23.
Crossref
Crossref
Gregory H. Underhill & Salman R. Khetani. (2019)
Emerging trends in modeling human liver disease
in vitro
. APL Bioengineering 3:4.
Crossref
Crossref
Ceri‐Anne E. Suurmond, Soufian Lasli, Floor W. Dolder, Aly Ung, Han‐Jun Kim, Praveen Bandaru, KangJu Lee, Hyun‐Jong Cho, Samad Ahadian, Nureddin Ashammakhi, Mehmet R. Dokmeci, Junmin Lee & Ali Khademhosseini. (2019) In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells. Advanced Healthcare Materials 8:24, pages 1901379.
Crossref
Crossref
Ian James Martins. 2019. Nonalcoholic Fatty Liver Disease - An Update. Nonalcoholic Fatty Liver Disease - An Update.
Selene de Jesús Acosta-Cota, Elsa Maribel Aguilar-Medina, Rosalío Ramos-Payán, José Guadalupe Rendón Maldonado, José Geovanni Romero-Quintana, Julio Montes-Avila, Juan I. Sarmiento-Sánchez, Carolina Gabriela Plazas-Guerrero, Marcela J. Vergara-Jiménez, Araceli Sánchez-López, David Centurión & Ulises Osuna-Martínez. (2019) Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease. European Journal of Pharmacology 863, pages 172699.
Crossref
Crossref
Eloy D. Hernandez, Lianxing Zheng, Young Kim, Bin Fang, Bo Liu, Reginald A. Valdez, William F. Dietrich, Paul V. Rucker, Donatella Chianelli, James Schmeits, Dingjiu Bao, Jocelyn Zoll, Claire Dubois, Glenn C. Federe, Lihao Chen, Sean B. Joseph, Lloyd B. Klickstein, John Walker, Valentina Molteni, Peter McNamara, Shelly Meeusen, David C. Tully, Michael K. Badman, Jie Xu & Bryan Laffitte. (2019) Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. Hepatology Communications 3:8, pages 1085-1097.
Crossref
Crossref
Soufian Lasli, Han‐Jun Kim, KangJu Lee, Ceri‐Anne E. Suurmond, Marcus Goudie, Praveen Bandaru, Wujin Sun, Shiming Zhang, Niyuan Zhang, Samad Ahadian, Mehmet R. Dokmeci, Junmin Lee & Ali Khademhosseini. (2019) A Human Liver‐on‐a‐Chip Platform for Modeling Nonalcoholic Fatty Liver Disease. Advanced Biosystems 3:8, pages 1900104.
Crossref
Crossref
Piero Pingitore, Kavitha Sasidharan, Matias Ekstrand, Sebastian Prill, Daniel Lindén & Stefano Romeo. (2019) Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis. International Journal of Molecular Sciences 20:7, pages 1629.
Crossref
Crossref
Love Sharma, Divya Gupta & Sheikh Tasduq Abdullah. (2019) Thioacetamide potentiates high cholesterol and high fat diet induced steato-hepatitic changes in livers of C57BL/6J mice: A novel eight weeks model of fibrosing NASH. Toxicology Letters 304, pages 21-29.
Crossref
Crossref
Selene de Jesús Acosta-CotaElsa Maribel Aguilar-MedinaRosalio Ramos-PayánAna Karen Ruiz-QuiñónezJosé Geovanni Romero-QuintanaJulio Montes-AvilaJosé Guadalupe Rendón-MaldonadoAraceli Sánchez-LópezDavid CenturiónUlises Osuna-Martínez. (2019) Histopathological and biochemical changes in the development of nonalcoholic fatty liver disease induced by high-sucrose diet at different times. Canadian Journal of Physiology and Pharmacology 97:1, pages 23-36.
Crossref
Crossref
Ajit Dash & William R. Proctor. 2019. Microfluidic Cell Culture Systems. Microfluidic Cell Culture Systems
159
186
.
Mikael Kozyra, Inger Johansson, Åsa Nordling, Shahid Ullah, Volker M. Lauschke & Magnus Ingelman-Sundberg. (2018) Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Scientific Reports 8:1.
Crossref
Crossref
Magnus Ingelman-Sundberg & Volker M Lauschke. (2018) Human liver spheroids in chemically defined conditions for studies of gene–drug, drug–drug and disease–drug interactions. Pharmacogenomics 19:14, pages 1133-1138.
Crossref
Crossref
Qiao Wu, Juan Liu, Lijin Liu, Yu Chen, Jie Wang, Ling Leng, Qunfang Yu, Zhongping Duan & Yunfang Wang. (2018) Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver. ACS Biomaterials Science & Engineering 4:8, pages 3016-3026.
Crossref
Crossref
Emilio Molina-Molina, Raquel Lunardi Baccetto, David Q.-H. Wang, Ornella de Bari, Marcin Krawczyk & Piero Portincasa. (2018) Exercising the hepatobiliary-gut axis. The impact of physical activity performance. European Journal of Clinical Investigation 48:8, pages e12958.
Crossref
Crossref
Avner Ehrlich, Sabina Tsytkin-Kirschenzweig, Konstantinos Ioannidis, Muneef Ayyash, Anne Riu, Reine Note, Gladys Ouedraogo, Jan Vanfleteren, Merav Cohen & Yaakov Nahmias. (2018) Microphysiological flux balance platform unravels the dynamics of drug induced steatosis. Lab on a Chip 18:17, pages 2510-2522.
Crossref
Crossref